Abstracts tagged "Lung Disease"

Abstract Number: 854 • 2017 ACR/ARHP Annual Meeting
Predictive Modeling of Mortality in Polymyositis/Dermatomyositis Patients with Interstitial Lung Disease Based on Combination of Serum Myositis-Specific Autoantibodies and Conventional Biomarkers
Takahisa Gono¹, Kenichi Masui², Yasushi Kawaguchi³, Kei Ikeda⁴, Atsushi Kawakami⁵, Maasa Tamura⁶, Yoshinori Tanino⁷, Takahiro Nunokawa⁸, Yuko Kaneko⁹, Shinji Sato¹⁰, Katsuaki Asakawa¹¹, Naoshi Nishina⁹ and Masataka Kuwana¹, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Department of Anesthesiology, National Defense Medical College School of Medicine, Tokorozawa, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, ⁵Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan, ⁶Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁷Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, Fukushima, Japan, ⁸Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, ⁹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁰Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan, ¹¹Division of Respiratory Medicine, Niigata University Medical and Dental Hospital, Niigata, Japan
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of mortality in patients with polymyositis or dermatomyositis (PM/DM). Since clinical courses and outcomes…
Abstract Number: 939 • 2017 ACR/ARHP Annual Meeting
Stimulator of Interferon Genes (STING)-Induced Endothelial-Mesenchymal Transition (EndMT) Contributes to Interstitial Lung Disease in Sting-Associated Vasculopathy with Onset in Infancy (SAVI) Patients
Louise Malle¹, Dan Yang², Adriana Almeida de Jesus¹, Guibin Chen², Bernadette Marrero¹, Gina A. Montealegre Sanchez¹, Yin Liu³, Gregor Dueckers⁴, Suzanne Ramsey⁵, Joseph Fontana⁶, Rachel VanTries¹, Yan Huang¹, Laisa Santiago⁷, Benito Gonzalez⁸, Paul Brogan⁹, Juergen Brunner¹⁰, Ebun Omoyinmi¹¹, Athimalaipet V. Ramanan¹², Amy Paller¹³, Olcay Y. Jones¹⁴, Seza Ozen¹⁵, Stephen R. Brooks¹⁶, Manfred Boehm¹⁷ and Raphaela Goldbach-Mansky¹, ¹Translational Autoinflammatory Disease Studies (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD, ²Center for Molecular Medicine, NHLBI/NIH, Bethesda, MD, ³Scientific Review Branch, NIAMS/NIH, Bethesda, MD, ⁴Helios Kliniken - Kinderklinik, HELIOS Klinikum Krefeld, Krefeld, Germany, ⁵Pediatric Rheumatology, IWK Health Centre, Dalhousie University, Halifax, NS, Canada, ⁶Cardiovascular and Pulmonary Branch, NHLBI/NIH, Bethesda, MD, ⁷Johns Hopkins All Children's Hospital Rheumatology, Saint Petersburg, FL, ⁸Luis Calvo Mackenna Hospital, Santiago, Chile, ⁹Infection Inflammation and Rheumatology, UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ¹⁰Division of Pediatric Rheumatology, Medical University Innsbruck, Innsbruck, Austria, ¹¹University College London Institute of Child Health, London, United Kingdom, ¹²Bristol Royal Hospital for Children, Bristol, United Kingdom, ¹³Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IN, ¹⁴Department of Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD, ¹⁵Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ¹⁶Biodata Mining and Discovery Section, Office of Science and Technology, NIAMS/NIH, Bethesda, MD, ¹⁷Center for Molecular Medicine, NHLBI/ NIH, Bethesda, MD
Background/Purpose: Pulmonary fibrosis, is a life-threatening complication of the monogenic autoinflammatory interferonopathy, STING-Associated Vasculopathy with onset in Infancy (SAVI) that is caused by gain-of-function mutations…
Abstract Number: 1486 • 2017 ACR/ARHP Annual Meeting
Interstitial Lung Disease in Primary Sjögren’s Syndrome : Clinical Presentation, Serological Biomarkers and Long Term Outcome
Chiara Baldini¹, Ilaria Puxeddu², Martina Orlandi³, Francesco Ferro⁴, Elena Elefante⁴, Nicoletta Luciano⁴, Marco Matucci-Cerinic³, Paola Migliorini² and Marta Mosca⁴, ¹Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ²Allergology and Clinical Immunology Unit, University of Pisa, Pisa, Italy, ³Rheumatology Unit, University of Florence, Florence, Italy, ⁴Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Interstitial lung disease (ILD) is a rare but potentially severe manifestation of primary Sjögren’s syndrome (pSS). The aims of this study were to: 1)…
Abstract Number: 1488 • 2017 ACR/ARHP Annual Meeting
Correlation between Lung Ultrasound, HRCT Findings and Pulmonary Function Tests in Primary Sjögren’s Syndrome (pSS)-Associated Interstitial Lung Disease
Francesco Ferro¹, Alessandra Bulleri², Andrea Delle Sedie¹, Simone Barsotti¹, Nicoletta Luciano¹, Elisa Cioffi³, Elena Elefante¹, Gianfranco Puppo⁴, Marta Mosca¹ and Chiara Baldini⁵, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Radiology Unit, University of Pisa, Pisa, Italy, ³Rheumatology Unit, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴Pneumology Unit, University of Pisa, Pisa, Italy, ⁵Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Recently, pleural irregularity (PI), a new lung ultrasound (US) sign, has been proposed as an emerging tool for the diagnosis of interstitial lung disease…
Abstract Number: 2188 • 2016 ACR/ARHP Annual Meeting
Association Between Extent of Symptomatic Joint Involvement in Osteoarthritis and Comorbid Lung Disease in Patients Scheduled for Joint-Replacement Surgery
Anthony V. Perruccio^1,2,3, Rajiv Gandhi⁴, J. Denise Power^5,6 and Elizabeth M. Badley⁷, ¹The Arthritis Program, University Health Network, Toronto, ON, Canada, ²Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ³Health Care & Outcomes Research, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴University Health Network, Arthritis Program, Toronto, ON, Canada, ⁵Arthritis Program, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁶Dalla Lana School of Public Health, Toronto, ON, Canada, ⁷Toronto Western Research Institute, Toronto, ON, Canada
Background/Purpose: Comorbidity is highly prevalent in osteoarthritis (OA), although the origin of this is not well understood. The presence of multi-joint symptoms in OA, and…
Abstract Number: 2189 • 2016 ACR/ARHP Annual Meeting
The Association of Arthritis and Lung Diseases: A Population-Based Study
Elizabeth M. Badley^1,2, Marcia Maguire¹ and Anthony V. Perruccio^1,3, ¹Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ³Arthritis Program, Toronto Western Hospital, University Health Network, Toronto, ON, Canada
Background/Purpose: While rheumatoid arthritis is associated with a number of different lung conditions, the relationship with osteoarthritis, overwhelmingly the most frequent type of arthritis in…
Abstract Number: 2326 • 2016 ACR/ARHP Annual Meeting
Intravenous Cyclophosphamide Followed By Oral Immunosuppressive Treatment Versus Rituximab in Inflammatory Myopathy-Related Interstitial Lung Disease
Vincent Langlois¹, Kuberaka Mariampillai², Nicolas Champtiaux³, Marie-Laure Chabi⁴, Yurdagul Uzunhan⁵, Eric Hachulla⁶, Olivier Benveniste⁷ and Baptiste Hervier³, ¹Internal Medicine, University Hospital, Rouen, France, ²Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Department of Internal Medicine and Clinical Immunology, Hospital University Department: inflammation, immunopathology and biotherapy (DHU i2B), Paris, France, Paris, France, ³Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ⁴Radiology department, APHP, Hôpital Pitié Salpêtrière, Paris, France, ⁵Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ⁶Internal Medicine, Lille University Hospital, Lille, France, ⁷Pitié-Salpêtrière University Hospital, Paris, France
Background/Purpose: Interstitial lung disease (ILD) associated with inflammatory myopathy (IM) has a poor prognosis and requires specific treatments. Intravenous Cyclophosphamide (CYC) is one of the…
Abstract Number: 2429 • 2016 ACR/ARHP Annual Meeting
Mechanisms for the Development of Lung Fibrosis in Sting-Associated Vasculopathy with Onset in Infancy (SAVI)
Adriana Almeida de Jesus¹, Louise Malle¹, Dan Yang², Bernadette Marrero¹, Yin Liu³, Gina A. Montealegre Sanchez¹, Dawn C. Chapelle⁴, Hanna Kim⁴, Michelle O'Brien⁴, Gregor Dueckers⁵, Suzanne Ramsey⁶, Joseph R. Fontana⁷, Steven M. Holland⁸, Yan Huang¹, Suvimol Hill⁹, Laisa Santiago¹⁰, Benito Gonzalez¹¹, Paul Brogan¹², Juergen Brunner¹³, Ebun Omoyinmi¹⁴, Athimalaipet V Ramanan¹⁵, Amy Paller¹⁶, Olcay Y. Jones¹⁷, Seza Ozen¹⁸, Stephen Brooks⁴, Zuoming Deng⁴, Manfred Boehm¹⁹, Raphaela Goldbach-Mansky²⁰ and Helmut Wittkowski²¹, ¹National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ²National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, MD, ³Scientific Review Branch, NIAMS, NIH, Bethesda, MD, ⁴NIAMS/NIH, Bethesda, MD, ⁵Helios Kliniken - Kinderklinik, HELIOS Klinikum Krefeld, Krefeld, Germany, ⁶Pediatric Rheumatology, IWK Health Centre, Halifax, NS, Canada, ⁷Cardiovascular and Pulmonary Branch, NHLBI, NIH, Bethesda, MD, ⁸Laboratory of Clinical Infectious Disease, NIAID, NIH, Bethesda, MD, ⁹Radiology Department, Clinical Center, NIH, Bethesda, MD, ¹⁰Johns Hopkins All Children's Hospital Rheumatology, Saint Petersburg, FL, ¹¹Luis Calvo Mackenna Hospital, Santiago, Chile, ¹²UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ¹³Department of Pediatrics, Medical University Innsbruck, Innsbruck, Austria, ¹⁴University College London Institute of Child Health, London, United Kingdom, ¹⁵University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom, ¹⁶Departments of Dermatology and Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA;, Chicago, IL, ¹⁷Pediatrics, Walter Reed National Military Medical Center, Bethesda, MD, ¹⁸Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, ANKARA, Turkey, ¹⁹Laboratory of Cardiovascular Regenerative Medicine, National Heart, Lung, and Blood Institute (NHLBI), NIH, Bethesda, MD, ²⁰Translational Autoinflammatory Disease Studies, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, ²¹Department of Pediatric Rheumatology and Immunology, University Hospital of Muenster, Münster, Germany
Background/Purpose: STING-Associated Vasculopathy with Onset in Infancy (SAVI) is a monogenic autoinflammatory interferonopathy caused by gain-of-function mutations in TMEM173/STING, a nucleic acid sensor adaptor linked…
Abstract Number: 2583 • 2016 ACR/ARHP Annual Meeting
Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Multicenter Study of 55 Patients
Carlos Fernández-Díaz¹, Javier Loricera¹, Santos Castañeda², Clara Ojeda-Garcia³, Alejandro Olivé⁴, Patricia E. Carreira⁵, Trinidad Perez Sandoval⁶, Miriam Retuerto⁷, Evelin Cecilia Cervantes Pérez⁸, Samantha Rodriguez-Muguruza⁴, Bryan Josue Robles Flores⁹, Blanca Hernández-Cruz¹⁰, Ana Urruticoechea¹¹, O. Maiz Alonso¹², Desiree Palma¹³, Luis Arboleya¹⁴, Gema Bonilla¹⁵, Íñigo Hernández-Rodríguez¹⁶, Concepción Delgado¹⁷, Rosa Expósito Molinero¹⁸, Ana Ruibal Escribano¹⁹, Juan Blanco Madrigal²⁰, José Antonio Bernal²¹, Manuel Rodríguez-Gómez²², Paloma Vela Casasempere²³, Belen Alvarez-Rodriguez²⁴, María Concepción Fito Manteca²⁵, Francisco Ortiz Sanjuan²⁶, Javier Narváez²⁷, Manuel Jose Moreno²⁸, Mireia Lopez-corbeto²⁹, Natalia Mena-Vazquez³⁰, Lucia C. Domínguez-Casas¹, Clara Aguilera-Cros³¹, Victor Mora-Cuesta³², Natalia Palmou-Fontana¹, Miguel Angel Gonzalez-Gay³³, José Luis Hernandez³⁴ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology, Hospital de la Princesa, IIS-IP, Madrid, Spain, ³Rheumatology, Hospital Virgen de la Macarena, Sevilla, Spain, ⁴Rheumatology, Hospital Universitario Germans Trias i Pujol, Barcelona, Spain, ⁵Multidisciplinary Pulmonary Hypertension Unit. Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Rheumatology, Hospital de León, LEÓN, Spain, ⁷Rheumatology, Hospital de Leon, Leon, Spain, ⁸Rheumatology, Hospital Santiago de Compostela, Santiago de Compostela, Spain, ⁹Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ¹⁰Rheumatology, Hospital Universitario Virgen Macarena, Sevilla, Spain, ¹¹Hospital Can Misses, Ibiza, Spain, ¹²Rheumatology, Hospital Donostia, San Sebastian, Spain, ¹³Rheumatology, Rafael Mendez Hospital, Spain., Lorca (Murcia), Spain, ¹⁴Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁵Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ¹⁶Rheumatology, CHUVI Vigo, Vigo, Spain, ¹⁷Rheumatology, Hospital Clinico Universitario Lozano Blesa, zaragoza, Spain, ¹⁸Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ¹⁹Rheumatology, Hospital Universitario de Araba, Vittoria, Spain, ²⁰Rheumatology, Hospital de Basurto, BIlbao, Spain, ²¹Sección de Reumatología, Hospital General de Alicante, Alicante, Spain, ²²Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ²³Rheumatology, Hospital General de Alicante, Alicante, Spain, ²⁴Hospital Txagorritxu, Vittoria, Spain, ²⁵Reumatología, Hospital de Navarra, Pamplona, Spain, ²⁶Rheumatology, Hospital La Fe, Valencia, Spain, ²⁷Rheumatology Department, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Spain, ²⁸Rheumatology, Hospital Virgen de la Arrixaca, MURCIA, Spain, ²⁹Hospital Universitario Vall d'Hebron, Barcelona, Spain, ³⁰Rheumatology, Hospital Universitario de Malaga, Malaga, Spain, ³¹Rheumatology, Hospital Virgen del Rocio, Sevilla, Spain, ³²Neumology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³³Department of RheumaRheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ³⁴Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Interstitial Lung Disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). A potential association of anti-TNFα drugs and conventional disease-modifying anti-rheumatic drugs…
Abstract Number: 2677 • 2016 ACR/ARHP Annual Meeting
Clinical Features of Primary Sjogren’s Syndrome Associated Lung Involvement with Extro-Glandular Manifestations at Onset
Hui Gao¹, Xuewu Zhang^1,2 and Zhan-Guo Li^1,3, ¹Peking University International Hospital, Beijing, China, ²Rheumatology, Peking University People's Hospital, Beijing, China, ³Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: To investigate the common initial clinical presentations of primary Sjogren’s syndrome with pulmonary complications, and to explore the differences between patients with extro-glandular manifestations…
Abstract Number: 2894 • 2016 ACR/ARHP Annual Meeting
Efficacy of Rituximab in Systemic Sclerosis with Interstitial Lung Disease
Ahmet Mesut Onat¹, Orhan Zengin¹, Savas Aksoy¹, Mustafa Erkut Onder¹, Koray Gorkem Sacıntı² and Bunyamin Kisacik¹, ¹Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, ²Gaziantep University, School of Medicine, Gaziantep, Turkey
Background/Purpose: Systemic sclerosis (SSc) is a progressive fibrotic and autoimmune disease, which results to severe systemic complications. Rituximab (Rtx), an anti CD-20 antibody, has recently…
Abstract Number: 179 • 2016 ACR/ARHP Annual Meeting
CD11b+Gr1dimcells, Which Are Induced By GM-CSF Produced By Th17 and Group3 Innate Lymphoid Cell, May Facilitate the Progression of Pneumonitis in SKG Mice
Sho Sendo¹, Jun Saegusa¹, Takaichi Okano², Soshi Takahashi³ and Akio Morinobu¹, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ³Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: Rheumatoid lung disease is a prognostic factors of rheumatoid arthritis in human. The pathogenesis and the mechanism of rheumatoid lung disease is unclear. Zymosan…
Abstract Number: 971 • 2016 ACR/ARHP Annual Meeting
Reliability and Minimal Clinically Important Differences (MCID) of Forced Vital Capacity: Post-Hoc Analyses from the Scleroderma Lung Studies (SLS-I and II)
Suzanne Kafaja¹, Philip J. Clements², Holly Wilhalme³, Daniel E. Furst⁴, Chi-hong Tseng², Kim Hyun⁵, Jonathan Goldin³, Elizabeth R. Volkmann³, Michael Roth², Donald P. Tashkin⁶ and Dinesh Khanna⁷, ¹Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵Radiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁶David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ⁷University of Michigan, Ann Arbor, MI
Background/Purpose: Forced vital capacity (FVC) is used as a primary outcome measure in clinical trials of systemic sclerosis-related interstitial lung disease (SSc-ILD). Minimally Clinically Important…
Abstract Number: 1016 • 2016 ACR/ARHP Annual Meeting
Soluble BAT-3: A New Biomarker for Antisynthetase Syndrome
Baptiste Hervier^1,2, Samra Ouaras², Laurent Gilardin³, Hanane Ouakrim⁴, Damien Amelin⁵, Fleur Cohen⁶, Yurdagul Uzunhan⁷, Yves Allenbach¹, Anne Bourgarit-Durand⁸, Olivier Benveniste⁹ and Vincent Vieillard¹⁰, ¹Internal Medicine, Pitié-Salpêtrière University Hospital, Paris, France, ²CIMI Paris, UMR-S 1135, INSERM & UPMC, Paris, France, ³Internal Medicine, APHP, Hôpital Pitié Salpêtrière, Paris, France, ⁴INSERM UMR-S 1138, Centre des cordeliers & APHP, Cochin Hospital, Laboratory of Pathology, Paris, France, ⁵Sorbonne Universités UPMC Univ Paris 06, Myology research center, INSERM UMRS974, CNRS FRE3617, Pitié-Salpêtrière University Hospital, Paris, France, Paris, France, ⁶Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ⁷Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ⁸CHU Bondy, Bondy, France, ⁹Pitié-Salpêtrière University Hospital, Paris, France, ¹⁰P&M Curie university, INSERM 543, Paris, France
Background/Purpose: Antisynthetase syndrome (ARS) is an inflammatory myopathy (IM) commonly associated to interstitial lung disease (ILD) and different anti-tRNA-synthetase autoantibodies. The immune mechanisms leading to…
Abstract Number: 1457 • 2016 ACR/ARHP Annual Meeting
Early Onset Morbidity and Mortality in Female Tumor Necrosis Factor Transgenic Mice with Inflammatory-Erosive Arthritis and Interstitial Lung Disease
Richard Bell¹, Emily Wu², Ronald Wood³, Joe Chakkalakal², Javier Rangel-Moreno⁴, Maria de la Luz Garcia-Hernandez², Christopher T. Ritchlin⁵, Edward Schwarz⁶ and Homaira Rahimi⁷, ¹Center for Musculoskelatal Research, University of Rochester, Rochester, NY, ²University of Rochaester, Rochester, NY, ³University of Rochester, Rochester, NY, ⁴Allergy, Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Orthopedeatrics, University of Rochester, Rochester, NY, ⁷Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY
Background/Purpose: Although exacerbated morbidity and mortality in rheumatoid arthritis (RA) is frequently seen in women, the etiology of this sexual dimorphism remains unclear. Previously, we…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].